Serum N-Desmethylcitalopram Concentrations are Associated with the Clinical Response to Citalopram of Patients with Major Depression
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objective Citalopram (CITA) is a widely used and well-tolerated selective serotonin reuptake inhibitor. The aim of the study was to evaluate the possible influences of serum concentrations of CITA and its major metabolite n-desmethylcitalopram (NDCITA) on the efficacy and tolerability of CITA in patients with major depressive disorder. Methods The study included 46 outpatients with major depressive disorder who received CITA. The efficacy and tolerability were assessed for 6 weeks. Serum CITA and NDCITA levels were measured at the 4th week. Results The HDRS17 total scores of the patients with high NDCITA and CITA & NDCITA concentrations showed a more significant reduction compared to the patients with expected and low serum NDCITA and CITA & NDCITA concentrations. However, we did not observe a correlation between the serum concentrations and the side effects of CITA, NDCITA, and CITA & NDCITA. Conclusion Our results suggested the potential contribution of NDCITA to the antidepressant effect of CITA. Further studies involving larger clinical samples are required to confirm the impact of serum NDCITA concentrations on the efficacy of CITA.
Abstract
Objective Citalopram (CITA) is a widely used and well-tolerated selective serotonin reuptake inhibitor. The aim of the study was to evaluate the possible influences of serum concentrations of CITA and its major metabolite n-desmethylcitalopram (NDCITA) on the efficacy and tolerability of CITA in patients with major depressive disorder. Methods The study included 46 outpatients with major depressive disorder who received CITA. The efficacy and tolerability were assessed for 6 weeks. Serum CITA and NDCITA levels were measured at the 4th week. Results The HDRS17 total scores of the patients with high NDCITA and CITA & NDCITA concentrations showed a more significant reduction compared to the patients with expected and low serum NDCITA and CITA & NDCITA concentrations. However, we did not observe a correlation between the serum concentrations and the side effects of CITA, NDCITA, and CITA & NDCITA. Conclusion Our results suggested the potential contribution of NDCITA to the antidepressant effect of CITA. Further studies involving larger clinical samples are required to confirm the impact of serum NDCITA concentrations on the efficacy of CITA.
참고문헌 (22)
- Trivedi MH, "Major depressive disorder: remission of associated symptoms", J Clin Psychiatry, 67(Suppl 6), pp.27~32 (2006)
- Karlsson H, "Remission in depression--is it a realistic goal?", Nord J Psychiatry, 62, pp.421~422 (2008)[DOI]
- Fava M, "Diagnosis and definition of treatment-resistant depression", Biol Psychiatry, 53, pp.649~659 (2003)[DOI]
- Hiemke C, "Therapeutic drug monitoring in neuropsychopharmacology: does it hold its promises", Eur Arch Psychiatry Clin Neurosci, 258(Suppl 1), pp.21~27 (2008)[DOI]
- Hiemke C, "AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011", Pharmacopsychiatry, 44, pp.195~235 (2011)[DOI]
- Muller MJ, "Therapeutic drug monitoring of tricyclic antidepressants: how does it work under clinical conditions?", Pharmacopsychiatry, 36, pp.98~104 (2003)[DOI]
- Wille SM, "Relevant issues in the monitoring and the toxicology of antidepressants", Crit Rev Clin Lab Sci, 45, pp.25~89 (2008)[DOI]
- Bezchlibnyk-Butler K, "Citalopram--a review of pharmacological and clinical effects", J Psychiatry Neurosci, 25, pp.241~254 (2000)
- Tatsumi M, "Pharmacological profile of antidepressants and related compounds at human monoamine transporters", Eur J Pharmacol, 340, pp.249~258 (1997)[DOI]
- Bjerkenstedt L, "Relationship between clinical effects, serum drug concentration and serotonin uptake inhibition in depressed patients treated with citalopram. A double-blind comparison of three dose levels", Eur J Clin Pharmacol, 28, pp.553~557 (1985)[DOI]
- Ostad Haji E, "Early improvement and serum concentrations of citalopram to predict antidepressant drug response of patients with major depression", Pharmacopsychiatry, 46, pp.261~266 (2013)[DOI]
- Ostad Haji E, "Association between citalopram serum levels and clinical improvement of patients with major depression", J Clin Psychopharmacol, 31, pp.281~286 (2011)[DOI]
- Ozbey G, "ABCB1 C3435T polymorphism is associated with susceptibility to major depression, but not with a clinical response to citalopram in a Turkish population", Pharmacol Rep, 66, pp.235~238 (2014)[DOI]
- Duverneuil C, "A high-performance liquid chromatography method with photodiodearray UV detection for therapeutic drug monitoring of the nontricyclic antidepressant drugs", Ther Drug Monit, 25, pp.565~573 (2003)[DOI]
- Charlier C, "Relationship between clinical effects, serum drug concentration, and concurrent drug interactions in depressed patients treated with citalopram, fluoxetine, clomipramine, paroxetine or venlafaxine", Hum Psychopharmacol, 15, pp.453~459 (2000)[DOI]
- Reis M, "Serum concentrations of antidepressant drugs in a naturalistic setting: compilation based on a large therapeutic drug monitoring database", Ther Drug Monit, 31, pp.42~56 (2009)[DOI]
- Reis M, "Serum levels of citalopram and its main metabolites in adolescent patients treated in a naturalistic clinical setting", J Clin Psychopharmacol, 22, pp.406~413 (2002)[DOI]
- Hicks JK, "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors", Clin Pharmacol Ther, 98, pp.127~134 (2015)[DOI]
- Wenzel-Seifert K, "Influence of concomitant medications on the total clearance and the risk for supra-therapeutic plasma concentrations of Citalopram. A population-based cohort study", Pharmacopsychiatry, 47, pp.239~244 (2014)[DOI]
- Klieber M, "CYP2C19 Phenoconversion by Routinely Prescribed Proton Pump Inhibitors Omeprazole and Esomeprazole: Clinical Implications for Personalized Medicine", J Pharmacol Exp Ther, 354, pp.426~430 (2015)[DOI]
- Deupree JD, "Pharmacological properties of the active metabolites of the antidepressants desipramine and citalopram", Eur J Pharmacol, 576, pp.55~60 (2007)[DOI]
- Hiemke C, "Clinical utility of drug measurement and pharmacokinetics: therapeutic drug monitoring in psychiatry", Eur J Clin Pharmacol, 64, pp.159~166 (2008)[DOI]